Findings

What do systematic reviews say?

4 questions · 5 findings · 2 reviews · Oral medicine and oral cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 4 · 80%Very low 1 · 20%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Related · question page
- EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) · Progression-free survival
  Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
  24 to 70 months · Monoclonal antibody + chemoradiotherapy vs chemoradiotherapy alone
  HR 1.08 [0.89, 1.32]
  1 study · 891 participants
  GRADE not reported
Related · question page
- Amifostine vs No treatment/placebo · Progression-free survival
  Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  12 to 24 months postRT
  HR 0.94 [0.70, 1.27]
  2 studies · 247 participants
  GRADE not reported
Related · question page
- Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) · Progression-free survival
  Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
  40 to 60 months
  HR 0.80 [0.51, 1.28]
  2 studies · 271 participants
  Very low
Related · question page
- Palifermin vs Placebo · Progression-free survival
  Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  42 to 72 months from baseline
  HR 1.06 [0.80, 1.42]
  3 studies
  GRADE not reported

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.

2 findings from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months · Monoclonal antibody + chemoradiotherapy vs chemoradiotherapy alone
HR 1.08 [0.89, 1.32]
1 study · 891 participants
GRADE not reported
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months · Monoclonal antibody + radiotherapy vs radiotherapy alone
HR 0.70 [0.54, 0.91]
1 study · 424 participants
GRADE not reported

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
40 to 60 months
HR 0.80 [0.51, 1.28]
2 studies · 271 participants
Very low

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Progression‐free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Palifermin showed no clear difference in progression-free survival compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
42 to 72 months from baseline
HR 1.06 [0.80, 1.42]
3 studies
GRADE not reported

Amifostine vs no treatment/placebo

Progression‐free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine showed no clear difference in progression-free survival compared with no treatment/placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
12 to 24 months postRT
HR 0.94 [0.70, 1.27]
2 studies · 247 participants
GRADE not reported